Melatonin prevents age-related hearing loss in the murin experimental model

Objective: The present study aimed to perform a morphological and morphometric analysis of cochlear structures of C57BL/6J mice receiving oral melatonin for a 12-month period. Methods: 32 male C57BL/6J were divided into control and melatonin groups. Control received saline and ethanol solution and m...

Full description

Bibliographic Details
Main Authors: Lucieny Silva Martins Serra, Juliana Gusmão de Araújo, Gabriela Novanta, Lucas Lauand, Eduardo Magalhães da Silva, Selma Aparecida Souza Kückelhaus, André Luiz Lopes Sampaio
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Brazilian Journal of Otorhinolaryngology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1808869422000829
Description
Summary:Objective: The present study aimed to perform a morphological and morphometric analysis of cochlear structures of C57BL/6J mice receiving oral melatonin for a 12-month period. Methods: 32 male C57BL/6J were divided into control and melatonin groups. Control received saline and ethanol solution and melatonin group, 50 μL of 10 mg of melatonin/kg/day orally for a 12-month period. After de experiment the animals were sacrificed into a 40% concentration of CO2 chamber, and the blades were morphological and morphometrically analyzed. Results: The melatonin group revealed a higher median density of viable cells (45 ± 10.28 cells/100 μm2, 31–73, vs. 32 ± 7.47 cells/100 μm2, 25–48). The median area of stria vascularis was 55.0 ± 12.27 cells/100 μm2 (38–80) in the control, and 59.0 ± 16.13 cells/100 μm2 (40–134) in the melatonin group. The morphometric analysis of the spiral ligament reveals a higher median of total viable neurons in the melatonin (41 ± 7.47 cells/100 μm2, 27–60) than in the control group (31 ± 5.68 cells/100 μm2, 21–44). Conclusion: Although melatonin is a potent antioxidant, it does not completely neutralize the occurrence of presbycusis; however, it may delay the onset of this condition. Level of evidence: 3.
ISSN:1808-8694